NLS Pharmaceutics

NLSP

Market cap $8.76M

Overview Fund Activity

2.06 USD

+0.03

1.48%

At close Updated Sep 18, 1:28 PM EDT

1 day

1.48%

5 days

-2.83%

1 month

-20.16%

3 months

-12.71%

6 months

32.9%

Year to date

-5.5%

1 year

-62.34%

5 years

-98.22%

10 years

-98.22%

About: NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Employees: 1

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding

Funds holding: 2 [Q1] → 4 (+2) [Q2]

79% more capital invested

Capital invested by funds: $261K [Q1] → $467K (+$207K) [Q2]

2.38% less ownership

Funds ownership: 6.86% [Q1] → 4.48% (-2.38%) [Q2]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

See Fund Rankings

Financial journalist opinion

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

ZURICH and NESS ZIONA, Israel , Sept. 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India Hong Kong represents a meaningful diabetes market and a critical gateway into Mainland China—including the Greater Bay Area—supporting future clinical collaboration, partnering and commercialization paths for IsletRx ZURICH , Sept. 4, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH , July 17, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, today announced that the Israel-U.S. Binational Industrial Research and Development Foundation (the "Bird Foundation") has approved another milestone-based funding payment to Kadimastem Ltd.

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed $3 million equity financing of preferred shares (or equivalents) and warrants from March 2025.

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH , June 16, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

ZURICH , May 21, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, announces that it will present new preclinical data on Mazindol ER at the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology ("ASCP").

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value markets beyond ADHD and narcolepsy ZURICH , April 15, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced positive results from Study KO-943, a preclinical investigation evaluating the efficacy of Mazindol in mitigating fentanyl-induced conditioned place preference (CPP) in mice.

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

The equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced the closing of a $2 million equity financing of preferred shares at a stated value of $1.65 per share, with a potential second closing of up to an additional $1 million of preferred shares at a purchase price of $1.65 per share.

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH , March 10, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

ZÜRICH, Switzerland , Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon Labs Inc. ("Aexon Labs"), is pleased to announce new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin receptor agonist ("DOXA") for narcolepsy and related neurological disorders.

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

See News Rankings

Charts implemented using Lightweight Charts™